Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancer

1 Sept 2021

Abstract excerpt

Background Tissue transglutaminase (TG2), an enzyme overexpressed in cancer cells, promotes metastasis and resistance to chemotherapy. Its distinct effects in cancer versus the host compartments have not been elucidated. Methods Here, by using a TG2-/- syngeneic ovarian cancer mouse model, we assessed the effects of TG2 deficiency in the host tissues on antitumor immunity and tumor progression. Multicolor flow...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipokines, Inflammation, and Metabolic Diseases
Share to Blood properties and coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34593619
DOI: 10.1136/jitc-2021-002682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancerPMID 34593619Read ↗

Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.Semantic proximity Read ↗

Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancerSemantic proximity Read ↗

Tissue transglutaminase: a new target to reverse cancer drug resistanceSemantic proximity Read ↗

Transglutaminase 2 exacerbates ovarian cancer survival by inactivating GSK3βSemantic proximity Read ↗

Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53Semantic proximity Read ↗

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetSemantic proximity Read ↗

Pan-Cancer Analysis of the Prognostic and Immunological Role of ECT2: A Promising Target for Survival and ImmunotherapySemantic proximity Read ↗

The Role of Transglutaminase 2 in Cancer: An UpdateSemantic proximity Read ↗

Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacySemantic proximity Read ↗

Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.Semantic proximity Read ↗

Roles of GFPT2 Expression Levels On the Prognosis and Tumor Microenvironment of Colon CancerSemantic proximity Read ↗

Roles of GFPT2 Expression Levels on the Prognosis and Tumor Microenvironment of Colon CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.